COMPASS PATHW SP.ADR Total Liabilities
COMPASS PATHW SP.ADR total liabilities. Based on the latest financial reports, COMPASS PATHW SP.ADR (5Y6) has total liabilities worth €420.03 Million EUR (≈ $491.06 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 5Y6 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Total Liabilities of COMPASS PATHW SP.ADR (2021–2025)
Total liabilities of COMPASS PATHW SP.ADR from 2021 to 2025. This chart illustrates how COMPASS PATHW SP.ADR's total liabilities have evolved over time, based on quarterly financial data. See 5Y6 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
COMPASS PATHW SP.ADR Competitors by Total Liabilities
The table below lists competitors of COMPASS PATHW SP.ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
|
USA | $65.96 Million |
|
The Star Entertainment Group Ltd
AU:SGR
|
Australia | AU$1.34 Billion |
|
Ronglian Group Ltd
SHE:002642
|
China | CN¥1.39 Billion |
|
Jiangsu Huaxicun Co Ltd
SHE:000936
|
China | CN¥1.46 Billion |
|
Hubei Radio and Television Information Network Co Ltd
SHE:000665
|
China | CN¥6.01 Billion |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥1.19 Billion |
|
Liberty Broadband Srs A
NASDAQ:LBRDA
|
USA | $1.94 Billion |
|
Biotest Aktiengesellschaft
XETRA:BIO3
|
Germany | €906.90 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down COMPASS PATHW SP.ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see COMPASS PATHW SP.ADR balance sheet assets.
Liquidity & Leverage Metrics
COMPASS PATHW SP.ADR Total Liabilities Ratios Explained
COMPASS PATHW SP.ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how COMPASS PATHW SP.ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for COMPASS PATHW SP.ADR (2021–2025)
The table below shows the annual total liabilities of COMPASS PATHW SP.ADR from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €263.20 Million ≈ $307.70 Million |
+346.32% |
| 2024-12-31 | €58.97 Million ≈ $68.94 Million |
+17.37% |
| 2023-12-31 | €50.24 Million ≈ $58.74 Million |
+213.74% |
| 2022-12-31 | €16.01 Million ≈ $18.72 Million |
-2.86% |
| 2021-12-31 | €16.49 Million ≈ $19.27 Million |
-- |
About COMPASS PATHW SP.ADR
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as … Read more